23 / 24
Not too rare to care
The rarity of MPS counts against early diagnosis
1–3
Collectively affecting only one in 22,500 births,
3
the
very rarity of mucopolysaccharidoses (MPSs), together
with a varied and subtle clinical presentation, make
early diagnosis difficult.
1,2,4
This can expose patients to
irreversible organ damage that treatment may prevent.
1,2,4
To assist in the diagnosis of rare diseases like MPS,
Sanofi Genzyme is providing paediatricians with access
to a highly-sophisticated differential checklist built on a
database of 6,000 diseases.
To register for
FREE* access visit
RDaware
.com.au*Free access until 14th May 2018.
References: 1. Meikle PJ
et al.
JAMA
1999; 281: 249-54. 2. Muenzer J.
J Pediatr
2004; 144: S27-S34.
3. Muenzer J
et al. Pediatrics
2009; 123 (1): 19-29. 4. Burton BK, Giugliani R.
Eur J Pediatr
2012; 171: 631-9.
sanofi-aventis Australia Pty Ltd trading as Sanofi Genzyme. ABN 31 008 558 807. Talavera Corporate Centre
Building D 12-24 Talavera Road. Macquarie Park, NSW 2113. GZANZ.ALDU.15.01.0025(1). July 2017. MPS0024